文献速递血栓与止血

表达工程化FVIII的细胞毒性T细胞在体外和体内靶向并杀伤FVIII特异性B细胞

Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.
PubMed 文献 · Blood Adv · 2018-01-01

血友病A患者接受FVIII替代治疗后20%至30%产生抑制性抗体。研究者将免疫优势FVIII结构域A2和C2构建为嵌合抗原受体,表达于人和鼠细胞毒性T细胞,形成FVIII结构域工程化B细胞抗体受体(BAR)T细胞。该细胞在体外和体内杀伤FVIII反应性B细胞杂交瘤,阻断多克隆刺激后特异性抗体产生,过继转移显著减少血友病小鼠抗FVIII抗体形成。

要点

  • 20%至30%接受FVIII替代治疗的血友病A患者产生中和性抗FVIII抗体(抑制物)。
  • FVIII A2和C2结构域工程化BAR CD8 T细胞在体外和体内杀伤FVIII反应性B细胞杂交瘤。
  • 过继转移FVIII A2和C2-BAR CD8 T细胞显著减少血友病小鼠抗FVIII抗体形成。

核心结论

  • BAR工程化T细胞可能成为未来对高抑制物风险的严重血友病A患者进行预防性治疗的有前景方法。

研究设计与样本

  • 将免疫优势FVIII结构域A2和C2构建为嵌合抗原受体,表达于人和鼠细胞毒性T细胞,在体外和体内评估其对FVIII特异性B细胞的靶向杀伤作用。

主要发现

  • FVIII结构域工程化BAR表达T细胞在体外和体内杀伤FVIII反应性B细胞杂交瘤。
  • FVIII BAR CD8 T细胞在体外阻断未免疫脾细胞经脂多糖多克隆刺激后特异性抗体的产生。
  • 过继转移FVIII A2和C2-BAR CD8 T细胞显著减少血友病小鼠的抗FVIII抗体形成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A is an X-linked bleeding disorder caused by mutations in the factor VIII (FVIII) gene (F8). Treatment with recombinant or plasma-derived FVIII replacement therapy is standard therapy. A major problem in treating hemophilia A patients with therapeutic FVIII is that 20% to 30% of these patients produce neutralizing anti-FVIII antibodies (inhibitors) because they are not immunologically tolerant to this human protein. Hence, there is a need to establish tolerogenic protocols to FVIII epitopes. To specifically target FVIII-specific B cells, we engineered immunodominant FVIII domains (A2 and C2) as a chimeric antigen receptor expressed by both human and murine cytotoxic T cells. This FVIII domain engineered B-cell antibody receptor (BAR) that expresses T cells was capable of killing FVIII-reactive B-cell hybridomas in vitro and in vivo. Moreover, FVIII BAR CD8 T cells blocked the development of specific antibody from unimmunized spleen cells stimulated polyclonally with lipopolysaccharide in vitro. In addition, adoptive transfer of FVIII A2- and C2-BAR CD8 T cells significantly reduced the anti-FVIII antibody formation in hemophilic mice. These data suggest that BAR-engineered T cells are a promising approach for future prophylactic treatment for patients with severe hemophilia A who are at high risk of developing inhibitors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Parvathaneni K, Scott DW. Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo. Blood Adv. 2018. PMID: 30232086. doi:10.1182/bloodadvances.2018018556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。